Plant ID: NPO23606
Plant Latin Name: Citrus Bergamia
Taxonomy Genus: Citrus
Taxonomy Family: Rutaceae
NCBI TaxonomyDB:
380129
Plant-of-the-World-Online:
n.a.
Ingredient ID: NPC74539
Ingredient ID: NPC322339
Ingredient ID: NPC120942
Target Type | Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|---|
Cytochrome P450 | Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 | Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Clinical trials associated with plant from natural product (NP) & plant level:
Clinical trials type | Number of clinical trials | |
---|---|---|
NP level | 323 | |
Plant level | 1 | |
NCT ID | Title | Condition | Form in clinical use | Associated by plant or compound |
---|---|---|---|---|
NCT00440947 | Induction/Simplification With Atazanavir + Ritonavir + Abacavir/Lamivudine Fixed-Dose Combination In HIV-1 Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00127972 | 2NN & CHARM Long-Term Follow-up Study | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00256828 | Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001087 | The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00398996 | A Study to Compare Three Existing Starting Points of Anti-Retroviral Therapy (ART) Initiation in HIV/Tuberculosis (TB) Co-infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000865 | The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00332306 | Safety and Efficacy of Two Once Daily Anti Retroviral Treatment Regimens Along With Anti-tuberculosis Treatment | tuberculosis;HIV infection | Lamivudine (NPC469972) | NP level |
NCT02607930 | Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01489046 | Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00002162 | A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00086359 | Comparison of Anti-HIV Drug Combinations to Prevent Mother-to-Child Transmission of HIV | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00126880 | AVX754 (a New Nucleoside Reverse Transcriptase Inhibitor [NRTI]) to Treat Drug-resistant HIV | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00338780 | Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia) | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00000870 | A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00132652 | Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00013897 | A Comparison of BMS-232632 With Efavirenz, Each in Combination With Zidovudine-Lamivudine | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00005918 | Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002233 | A Study of a Combination of Four Drugs in Patients With Recent HIV Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01352715 | Study of Options for Second-Line Effective Combination Therapy (SELECT) | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00354653 | A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00002410 | A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00915655 | A Study to Evaluate Antiviral Activity of Darunavir + Ritonavir in HIV-1 Infected Adolescents | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT04552795 | Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease | Alzheimer disease | Lamivudine (NPC469972) | NP level |
NCT00002241 | Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02616783 | Switching From a Tenofovir Disoproxil Fumarate (TDF) Containing Regimen to Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide (E/C/F/TAF) Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Adults Aged ≥ 60 Years | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01751555 | Efficacy and Safety of TDF+3TC+EFV in Adults With HIV/HBV Coinfection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01353742 | Lamivudine and Adefovir Dipivoxil Fixed Dose Combination | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00000834 | A Phase I Study of Methotrexate for HIV Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002208 | A Multicenter, Open-Label, Randomized, 24-Week Study to Compare the Safety and Activity of Indinavir Sulfate, 800 Mg q 8 h Versus 1,200 Mg q 12 h in Combination With Zidovudine and 3TC | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01900106 | A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00612898 | Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000944 | A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00038220 | Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00643968 | Tenofovir DF + Efavirenz (TDF+EFV) Versus Tenofovir DF + Efavirenz + Lamivudine (TDF+EFV+3TC) Maintenance Regimen in Virologically Controlled Patients: COOL Trial | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00005017 | Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002183 | A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001068 | A Study of Disease Progression and Anti-HIV Treatments | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000916 | A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02403674 | Comparison of Doravirine, Tenofovir, Lamivudine (MK-1439A) and ATRIPLA™ in Treatment-Naive Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Participants (MK-1439A-021) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00772902 | ROCKET II - Randomized Open Label Switch for Cholesterol Elevation on Kivexa + Kaletra Evaluation Trial | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00427297 | Optimizing Pediatric HIV-1 Treatment in Infants With Prophylactic Exposure to Nevirapine, Nairobi, Kenya | HIV infection | Lamivudine (NPC469972) | NP level |
NCT03178084 | Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio | AIDS | Lamivudine (NPC469972) | NP level |
NCT01608269 | Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002389 | The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00013520 | Comparison of Three Different Initial Treatments Without Protease Inhibitors for HIV Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000885 | Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320 | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00041327 | Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma | lymphoma | Lamivudine (NPC469972) | NP level |
NCT00272480 | Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial | tropical spastic paraparesis | Lamivudine (NPC469972) | NP level |
NCT02202473 | Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT01620944 | Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000918 | A Study to Compare The Ability of Different Anti-HIV Drugs to Decrease Viral Load After Nelfinavir (an Anti-HIV Drug)Treatment Failure | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002397 | A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease | HIV-associated nephropathy | Lamivudine (NPC469972) | NP level |
NCT02560649 | An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00084136 | Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04697121 | Artichoke and Bergamot Phytosome | Hypercholesterolemia | Citrus Bergamia | Plant level As single plant |
NCT00120796 | Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2) | hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00312091 | Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00244712 | Abacavir/Lamivudine Versus Emtricitabine/Tenofovir Both In Combination With Lopinavir/Ritonavir For The Treatment Of HIV | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04880395 | Dolutegravir-Lamivudine for naïve HIV-Infected Patients With ≤200 CD4/mm3 | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00000841 | A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04433780 | DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01772940 | Nevirapine vs Ritonavir-boosted Lopinavir in ART Naive HIV-infected Adults in a Resource Limited Setting | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT03360682 | Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01127204 | Evaluation of Simplified Antiretroviral Treatment Strategies in HIV Infected Children Treated by Antiretroviral (ARV) Before One Year of Age | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00230477 | Hepsera Versus Hepsera Plus Lamivudine for Treatment of Chronic Hepatitis B in Patients With Normal ALT | hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00158821 | Study of Treatment of Antiretroviral-naive, HIV-1-Infected Patients Comparing Tenofovir Disoproxil Fumarate Administered in Combination With Lamivudine and Efavirenz vs. Stavudine, Lamivudine and Efavirenz. | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02246998 | Renal Effect of Stribild or Other Tenofovir DF-containing Regimens Compared to Ritonavir-boosted Atazanavir Plus Abacavir/Lamivudine in Antiretroviral Treatment-naive HIV-1 Infected Adults | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00031070 | Increasing HAART-Induced Immune Restoration With Cyclosporine | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00979706 | Immune-based Therapy Pilot Study for the Treatment of Primary HIV Infection (PHI-IMD). | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002199 | A Phase III Randomized Double-Blind, Multicenter Study to Evaluate the Safety and Efficacy of 3TC/ZDV/1592U89 and 3TC/ZDV/IDV in HIV-1 Infected Antiretroviral Therapy-Naive Subjects. | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001968 | Once-Daily Drug Regimen for HIV-Infected Patients | AIDS | Lamivudine (NPC469972) | NP level |
NCT02075593 | ING200336, Pharmacokinetic and Safety Study in Pregnant Women With Human Immuno Virus Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002227 | A Study of Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00798460 | Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT01599364 | Atazanavir/r + Lamivudine Dual Therapy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01597934 | Antiviral Efficacy of Switching to ETV Plus TDF | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00002391 | The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002379 | The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00885482 | Atazanavir and Lamivudine for Treatment Simplification | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001644 | Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002368 | The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00312039 | Study of Once Daily Elvucitabine Versus Lamivudine in Subjects With a Documented M184V Mutation | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00192634 | A Randomised, Open-label Trial to Assess the Safety and Efficacy of Switching to Tenofovir-emtricitabine or Abacavir-lamivudine: The STEAL Study | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02181933 | Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00350272 | Elvucitabine/Efavirenz/Tenofovir vs. Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected, Treatment Naive Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00146380 | A Study of Zidovudine/Lamivudine and Either Nevirapine or Nelfinavir for Reduction of Mother-to-child HIV Transmission During Breastfeeding | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000899 | A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01982396 | Pharmacokinetic (PK) Study of Twice Daily vs Once Daily Lamivudine (3TC) and Abacavir (ABC) as Part of Combination Antiretroviral Therapy (ART) in HIV Infected Children | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00380614 | A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B | hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00085943 | KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02652260 | Effects of Switching From ATRIPLA™ (Efavirenz, Tenofovir, Emtricitabine) to MK-1439A (Doravirine, Tenofovir, Lamivudine) in Virologically-Suppressed Participants (MK-1439A-028) | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT02263326 | Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00005000 | Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001108 | A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00143728 | 3TC or No 3TC for HIV With 3TC Resistance | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00624195 | Clinical Trial of CNS-targeted HAART (CIT2) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000838 | Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02300623 | Intermittent ART in Primary HIV Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00810524 | Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT01656122 | Abacavir and Lamivudine PK in Children | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00131742 | Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00094367 | A Study Comparing Safety Of Abacavir And Lamivudine Administered Once-Daily As A Single Tablet Versus The Same Drugs Administered Twice-Daily As Separate Tablets (ALOHA Study) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002234 | Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001091 | Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01061151 | Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02499874 | SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00799864 | A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00143689 | NRTI-Sparing Pilot Study | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01307488 | Simplification to Atazanavir/Ritonavir + Lamivudine as Maintenance Therapy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00324649 | Peripheral Body Fat Distribution After Switching Zidovudine and Lamivudine to Truvada | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00338390 | Study to Evaluate Changes in CD4 on Replacing TDF With ABC or DDI+TDF With ABC+3TC | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00605384 | A Phase IIIb Study to Compare Entecavir Plus Tenofovir vs. Adefovir Added to Continuing Lamivudine Therapy in Adult Patients With Lamivudine-Resistant Hepatitis B Infection | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00823550 | Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00078247 | Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis | tuberculosis;HIV infection | Lamivudine (NPC469972) | NP level |
NCT02067767 | Multicentric Open-label Study of Switch From Abacavir/Lamivudine Fixed Dose Combination Plus Nevirapine to Abacavir/Lamivudine/Dolutegravir in Virologically Suppressed HIV-1 Infected Adults (SWAD) | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00004736 | Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00337922 | Pharmacokinetic Study Of EPZICOM Tablet | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00335192 | To Determine if There Are Pharmacokinetic Interactions at Plasma or Intracellular Level Between Nucleosides and Tenofovir | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00549198 | KIVEXA Vs TRUVADA, Both Administered With Efavirenz, In ART-Naive Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002429 | Evaluation of an Anti-HIV Drug Combination That Includes a Coated Form of Didanosine (ddI EC) Compared to a Typical Anti-HIV Drug Regimen | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00076336 | Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis | chronic hepatitis B virus infection;Hepatitis | Lamivudine (NPC469972) | NP level |
NCT00405925 | FREE Study: Efficacy and Toxicity of Trizivir | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00057265 | A Randomized, Double Blind Trial of LdT (Telbivudine) Versus Lamivudine in Adults With Compensated Chronic Hepatitis B | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00002245 | A Study of the Effects of Amprenavir, a Protease Inhibitor, on Carbohydrate and Fat Metabolism in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00004585 | A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02598063 | A Study to Evaluate Efficacy and Safety of Peginterferon Alfa-2a (Pegasys) and Adeforvir Dipivoxil (ADV) in Participants With Lamivudine-Resistant Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00017719 | Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01469520 | Bioequivalence Study of Pediatric Formulations to Treat HIV Infection | AIDS | Lamivudine (NPC469972) | NP level |
NCT00002423 | A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00158405 | Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00226447 | Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00102206 | A Comparison of Two Anti-HIV Drug Regimens for Youth Who Have Failed Prior Therapy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002409 | The Effect of Teaching HIV-Infected Patients About HIV and Treatment | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002320 | A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01227824 | A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001085 | A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00095121 | Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00001083 | Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT03869944 | Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01511237 | Perinatal Antiretroviral Intensification for PMTCT of HIV in Late Comers | HIV infection | Lamivudine (NPC469972) | NP level |
NCT03272347 | Islatravir (MK-8591) With Doravirine and Lamivudine in Participants Infected With Human Immunodeficiency Virus Type 1 (MK-8591-011) | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00615810 | ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00985647 | Pharmacokinetics of Lamivudine at Two Different Doses | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00424814 | Prevention of HIV1 Mother to Child Transmission Without Nucleoside Analogue Reverse Transcriptase Inhibitors in the Pre-partum Phase. ANRS 135 Primeva | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000891 | Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315 | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00112047 | Tenofovir Disoproxil Fumarate/Emtricitabine/Efavirenz Versus Combivir/Efavirenz in Antiretroviral-Naive HIV-1 Infected Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001066 | A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02219672 | Study on the Impact of Triptolide Woldifiion on HIV-1 Reservoir In Acute HIV-1 Infection | AIDS | Lamivudine (NPC469972) | NP level |
NCT00724711 | Safety and Efficacy Study of Switching From Epzicom to Truvada | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01366547 | Relative Bioavailability Study of Two New Dolutegravir/Abacavir/Lamivudine Fixed Dose Combination Tablets | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02249130 | Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002416 | Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02120352 | A Phase IIb Study to Evaluate a Long-Acting Intramuscular Regimen for Maintenance of Virologic Suppression (Following Induction With an Oral Regimen of GSK1265744 and Abacavir/Lamivudine) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected, Antiretroviral Therapy-Naive Adult Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00672412 | Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00428116 | Optimizing Pediatric HIV-1 Treatment, Nairobi, Kenya | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01718587 | Difference in Efficacy Between Stem Cell Transplantation and Classical Therapy in Liver Cirrhosis Patients | cirrhosis of liver | Lamivudine (NPC469972) | NP level |
NCT02369965 | Test Albuvirtide in Experienced Patients | AIDS | Lamivudine (NPC469972) | NP level |
NCT02596334 | Study to Evaluate the Efficacy of MONotherapy of TiviCAY® Versus a Triple Therapy in HIV-1-infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02431975 | Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01438424 | Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials | hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00140725 | Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV) | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT02337127 | Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00000872 | Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00084149 | Cyclosporine A in Combination With Abacavir Sulfate, Lamivudine, and Zidovudine and Lopinavir/Ritonavir in HIV | HIV infection | Lamivudine (NPC469972) | NP level |
NCT03333083 | Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00011895 | Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02159599 | Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002386 | Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02582684 | Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT02539576 | Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00625339 | Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT02116660 | Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02397096 | Safety and Efficacy of a Switch to Doravirine, Tenofovir, Lamivudine (MK-1439A) in Human Immunodeficiency Virus (HIV-1)-Infected Participants Virologically Suppressed on an Anti-retroviral Regimen in Combination With Two Nucleoside Reverse Transcriptase Inhibitors (MK-1439A-024) | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00966160 | CD4 Cell Recovery in HIV-1 Patients Comparing 2 Treatment Regimes | AIDS | Lamivudine (NPC469972) | NP level |
NCT02211482 | Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT02603120 | Safety and Efficacy of Switching From Dolutegravir and ABC/3TC or ABC/DTG/3TC to B/F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00008554 | Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00740064 | Pilot Study With Isentress (Raltegravir) and Epzicom (Abacavir/Lamivudine) in Treatment Naive HIV-Infected Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02131025 | A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00004583 | A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01732367 | TDF VS LAM + ADV in LAM + ADV Treated LAM-resistant CHB Patients With Undetectable Hepatitis B Virus DNA | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00014014 | Zidovudine and Lamivudine Given Once Versus Twice Daily | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00531167 | Adding Adefovir Dipivoxil Versus Switching to Entecavir in Patients With Lamivudine-resistant Chronic Hepatitis B | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00120783 | Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01263015 | A Trial Comparing GSK1349572 50mg Plus Abacavir/Lamivudine Once Daily to Atripla (Also Called The SINGLE Trial) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00314626 | Antiretroviral Treatment Simplification Study With Efavirenz + Abacavir + 3TC Once Daily | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002451 | Safety and Effectiveness of Giving Indinavir, Ritonavir, Stavudine, and Lamivudine to HIV-Infected Patients Who Have Never Received Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002442 | A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00380159 | Open-Label, 48 Week Extension Study of Elvucitabine in Combination With Background ART For Subjects Who Have Completed Study ACH443-014A | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00005002 | Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00053638 | A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01174914 | Effectiveness Study Low-Dose Naltrexone Versus ARV's for HIV+ | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04022967 | ANRS 12372 MODERATO Study | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00122538 | Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME) | AIDS | Lamivudine (NPC469972) | NP level |
NCT04696575 | Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer | small cell lung carcinoma | Lamivudine (NPC469972) | NP level |
NCT00625560 | Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT01088009 | Efficacy Optimizing Research of Lamivudine Therapy | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT01618305 | Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00640263 | Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002436 | The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04549467 | Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00316719 | Adefovir Dipivoxil In Compensated Chronic Hepatitis B Patients | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT02603107 | Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT03311945 | Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00164736 | Breastfeeding, Antiretroviral, and Nutrition Study | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00197613 | The Adult Antiretroviral Treatment and Resistance Study (Tshepo) | AIDS | Lamivudine (NPC469972) | NP level |
NCT00074581 | Preventing Sexual Transmission of HIV With Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00034359 | Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00275652 | A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis. | cirrhosis of liver;hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00335270 | A Randomized, Prospective Study of the Efficacy, Safety and Tolerability of Two Doses of GW433908Ritonavir Given With Abacavir/Lamivudine Fixed Dose Combination | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002179 | The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02482272 | Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT02105987 | A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002367 | A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02777229 | Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT02469246 | Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00344760 | A Study to Evaluate of the Efficacy of Enfuvirtide During the Induction Phase of Therapy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001084 | A Study of Three Treatment Combinations Using Zidovudine Plus Lamivudine Plus Indinavir in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00043953 | Lopinavir/Ritonavir in Combination With Saquinavir Mesylate or Lamivudine/Zidovudine to Explore Metabolic Toxicities in Antiretroviral HIV-Infected Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00410202 | Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00000882 | Virologic and Immunologic Activity of Continued Lamivudine (3TC) vs Delavirdine (DLV) in Combination With Indinavir (IDV) and Zidovudine (ZDV) or Stavudine (d4T) in 3TC-Experienced Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04884139 | DTG/3TC vs. BIC/FTC/TAF Maintenance Therapy in People Living With HIV: | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00002376 | The Effectiveness of HIV RNA Viral Load Testing in Determining Treatment Type in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00050895 | Comparing the Safety, Effectiveness, and Tolerability of Three Anti-HIV Drug Regimens for Treatment-Naive Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00986778 | Entecavir Plus Adefovir in Lamivudine-Resistant Patients | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00102960 | Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00336778 | Phase 1 Pilot Study of an ART Bridging Regimen in Highly Experienced Patients Unable to Achieve Viral Suppression | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02369406 | Early Infant HIV Treatment in Botswana | AIDS | Lamivudine (NPC469972) | NP level |
NCT02028676 | Efficacy Study of Different Laboratory Management Strategies and Drug Regimens in HIV-infected Children in Africa | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00124241 | An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B | hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00001067 | The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00044577 | New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04303598 | Phase III Clinical Study of Azvudine in Hiv-infected Treatment Naive Patients | infection | Lamivudine (NPC469972) | NP level |
NCT00158470 | Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00135369 | Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00099359 | Trial of Three Neonatal Antiretroviral Regimens for Prevention of Intrapartum HIV Transmission | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02605954 | Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01627223 | Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00001094 | A Comparison of Nelfinavir Plus Saquinavir Plus Delavirdine or 3TC/ZDV Versus Nelfinavir Plus 3TC/ZDV in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00533195 | Comparison of UVA1 Phototherapy Versus Photochemotherapy for Patients With Severe Generalized Atopic Dermatitis | atopic eczema | Bergapten (NPC74539) | NP level |
NCT05295394 | Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01546116 | Adefovir and Lamivudine for Entecavir Resistance (ALTER Study) | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT02150993 | First-Line Treatment for HIV-2 | infection | Lamivudine (NPC469972) | NP level |
NCT00000831 | Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00098293 | Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00201318 | A Randomized Study in Non-Hodgkin's Lymphoma Patients Carrying Hepatitis B Surface Antigen | non-Hodgkins lymphoma | Lamivudine (NPC469972) | NP level |
NCT01528865 | Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma | lymphoma | Lamivudine (NPC469972) | NP level |
NCT00273975 | Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT03539224 | Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept. | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00005106 | A Comparison of Three Anti-HIV Drug Combinations in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04585737 | Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00004981 | Safety and Effectiveness of Three Anti-HIV Drugs Combined in One Pill (Trizivir) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04704024 | Reducing Vertical Transmission of Hepatitis B in Africa | hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00000903 | Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00234923 | Efficacy and Safety of Kaletra Monotheraphy Compared to Kaletra Based Triple Therapy to Treat HIV in Antiretroviral Naїve Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00637663 | Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable Hepatitis B Virus DNA | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00710216 | Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT01936233 | Clinical Study of Antiviral and Aspirin Treatment in Liver Cancer After Radical Surgery | hepatocellular carcinoma | Lamivudine (NPC469972) | NP level |
NCT01829802 | RAL+ATV/r in Comparison With TDF/FTC (or 3TC) +ATV/r in HIV Infected Patients | infection | Lamivudine (NPC469972) | NP level |
NCT00100048 | A Study to Evaluate the Safety and Efficacy of an Investigational Drug in HIV Infected Patients (0518-004)(COMPLETED) | AIDS | Lamivudine (NPC469972) | NP level |
NCT00004578 | ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00046176 | A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00004998 | Safety and Effectiveness of a New Anti-HIV Drug (AG1549) in Combination With Other Anti-HIV Drugs in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00001095 | A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01928511 | Efficacy of Switching or Adding Pegylated Interferon in Chronic Hepatitis B Patients on Long Term Oral Antiviral Therapy | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT01005238 | Telbivudine Versus Lamivudine for Maintenance Therapy of Patients With Chronic Hepatitis B and Negative HBV Viral Load After 6 Month of Treatment With Telbivudine | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00099632 | Comparison of Three Anti-HIV Regimens to Prevent Nevirapine Resistance in Women Who Take Nevirapine During Pregnancy | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04429152 | ADORE: Efficacy of DORavirine in Adults Living With HIV Experiencing Virological Failure on First-line Efavirenz-based Antiretroviral Therapy With NNRTI Resistance | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00002124 | A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3 | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00009061 | Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002184 | A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient | HIV infection | Lamivudine (NPC469972) | NP level |
NCT04155554 | Neurological Monitoring in Patients Switching From Dolutegravir Based Regimen to Bictegravir Based Regimen | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01641809 | Dose Ranging Study of GSK1265744 Plus Nucleoside Reverse Transcriptase Inhibitors for Induction of Human Immunodeficiency Virus-1 (HIV-1) Virologic Suppression Followed by Virologic Suppression Maintenance by GSK1265744 Plus Rilpivirine | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00270296 | Trizivir Vs. Kaletra and Combivir for the Prevention of Mother-to-Child Transmission of HIV | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000901 | Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00618176 | Three Generic Nevirapine-Based Antiretroviral Treatments in Chinese Patients:Multicentric Observation Cohort | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00834457 | A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe | Kaposi's sarcoma | Lamivudine (NPC469972) | NP level |
NCT01160120 | Therapeutic Drug Monitoring (TDM) in Generic Tenofovir/Lamivudine/Efavirenz | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000902 | A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00004852 | Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00544128 | Comparison of Epzicom and Truvada for the Initial Once Daily HIV Treatment | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00234091 | When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00943540 | Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00028327 | Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00002424 | A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02284035 | Safety & Efficacy of Dual Therapy With Raltegravir/Lamivudine | AIDS | Lamivudine (NPC469972) | NP level |
NCT00118898 | Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00342355 | Antiretroviral Therapy for Advanced HIV Disease in South Africa | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02566707 | Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00038506 | Study Of Investigational Regimen Combining FDA Approved HIV Drugs In HIV Subjects Experiencing Early Virologic Failure | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00144183 | A Study of Single Dose Nevirapine (NVP) Combined With Combivir® for the Prevention of Mother to Child Transmission (pMTCT) - Treatment Options Preservation Study (TOPS) | AIDS | Lamivudine (NPC469972) | NP level |
NCT01905059 | Evaluation of a Maintenance Strategy With Protease Inhibitors With or Without Lamivudine in Virologically Suppressed HIV Patients on Second Line Antiretroviral Treatment in Africa | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00004999 | Effectiveness of a New Anti-HIV Drug (AG1549) Plus Viracept (Nelfinavir) Plus Combivir (Zidovudine/Lamivudine) in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT02770508 | Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01622790 | Evaluation of the Bioequivalence of a Combined Formulated Tablet | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01848743 | Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00002378 | A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00116298 | Rollover Study for Zerit (Stavudine) ER Studies (-096, -099) | AIDS | Lamivudine (NPC469972) | NP level |
NCT00002195 | A Study of Retrovir and Epivir Alone or in Combination With 141W94 in HIV-Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00000940 | Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00627055 | Second-line Therapy Antiretroviral in Patients Who Failed Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) - Based Regimens | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01714414 | A Trial to Confirm a Sustained Virological Suppression Defined as HIV-RNA <50 Copies/ml of 3 Different Doses of Fozivudine in Context to a Standard Zidovudine Based Antiretroviral Therapy Regimen | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00393484 | A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT05193994 | Triumeq in Amyotrophic Lateral Sclerosis | amyotrophic lateral sclerosis | Lamivudine (NPC469972) | NP level |
NCT01023217 | Entecavir Plus Adefovir in Lamivudine-Resistant Chronic Hepatitis B Patients Who Fail Lamivudine Plus Adefovir | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT01491295 | Switch to Tenofovir Versus Continue Lamivudine/Adefovir Treatment in Lamivudine-resistance Chronic Hepatitis B Patients | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT02629822 | Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT03870438 | Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT01910402 | A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00135382 | Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01386970 | Effect of Gender and HIV Infection on Zidovudine and Lamivudine Pharmacokinetics | HIV infection | Lamivudine (NPC469972) | NP level |
NCT03236584 | Tenofovir Monotherapy in Patients With Chronic Hepatitis B Patients Who Had Achieved Complete Viral Suppression on Lamivudine Plus Adefovir | hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00084253 | Study of Boosted Atazanavir (ATV) Versus Non-boosted ATV in Naive Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00455585 | Comparison of Plasma Drug Levels of Triomune 40 With Those of the Originator Products | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00433056 | Long Term Treatment Interruptions | AIDS | Lamivudine (NPC469972) | NP level |
NCT00002190 | A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients | HIV infection | Lamivudine (NPC469972) | NP level |
NCT01095835 | A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV) | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00002371 | The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00650637 | A Study to Determine Effective Prophylaxis and Treatment of Nelfinavir-Associated Diarrhea | Diarrhea | Lamivudine (NPC469972) | NP level |
NCT01804387 | Comparison of Telbivudine Plus Adefovir With Lamivudine Plus Adefovir for the Treatment of Lamivudine-resistant Chronic Hepatitis B at 52 Weeks: A Pilot Study | chronic hepatitis B virus infection | Lamivudine (NPC469972) | NP level |
NCT00958100 | Raltegravir Switch for Toxicity or Adverse Events | AIDS | Lamivudine (NPC469972) | NP level |
NCT04296695 | Biktarvy in Treatment-Naïve Late Presenters With HIV-1 Infection | HIV-1 infection | Lamivudine (NPC469972) | NP level |
NCT00000952 | A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children | HIV infection | Lamivudine (NPC469972) | NP level |
NCT00307151 | Antiviral Responses to NNRTI-Based vs. PI-Based ARV Therapy in HIV Infected Infants Who Have or Have Not Received Single Dose NVP for Prevention of Mother-to-Child Transmission of HIV | HIV infection | Lamivudine (NPC469972) | NP level |
How do we define the Plant-Targeted Human Disease Association?
Associated human diseases of an individual plant are summurized based on FOUR types of association evidence, these include:
❶ Association by Therapeutic Target: Bioactive protein targets of the plant were defined in "Molecular Targets" section, target-disease associations collected from TTD database were subsequently used to build the associations between the plant and its targeted human diseases.
❷ Association by Disease Gene Reversion: Plant and a specific disease will be associated when >= 1 plant target gene overlaped with disease's DEGs.
❸ Association by Clinical Trials of Plant: Plant and a specific disease will be associated when >= 1 clinical trial (the plant is the intervetion) can be matched in ClinicalTrials.gov database.
❹ Association by Clinical Trials of Plant Ingredients: Plant and a specific disease will be associated when >= 1 clinical trial (the plant ingredient is the intervetion) can be matched in ClinicalTrials.gov database.
Associated Disease of the Plant |
Association Type & Detailed Evidence |
---|---|
Chronic hepatitis B, unspecifiedDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1E51.0Z |
NCT01848743,NCT00393484,NCT01804387,NCT01023217,NCT00354653,NCT03236584,NCT02560649,NCT04704024,NCT02202473,NCT00810524,NCT00034359,NCT01005238,NCT00823550,NCT00131742,NCT00338780,NCT01732367,NCT00625339,NCT02482272,NCT01353742,NCT00710216,NCT00798460,NCT00120796,NCT00625560,NCT00095121,NCT00986778,NCT02337127,NCT01088009,NCT00226447,NCT01928511,NCT00230477,NCT01546116,NCT00124241,NCT00275652,NCT00637663,NCT00316719,NCT00531167,NCT02598063,NCT00132652,NCT01597934,NCT01491295,NCT00140725,NCT01627223,NCT00605384,NCT01095835,NCT01438424,NCT00410202,NCT00380614,NCT00057265,NCT00076336
|
Human immunodeficiency virus type 1Disease Category: X.Extension CodesDisease ICD-11 Code: XN8LD |
NCT02603107,NCT03360682,NCT04585737,NCT02629822,NCT03333083,NCT02246998,NCT03869944,NCT02582684,NCT02067767,NCT00324649,NCT00380159,NCT04022967,NCT00915655,NCT02616783,NCT02607930,NCT00098293,NCT04433780,NCT03539224,NCT02211482,NCT02652260,NCT02397096,NCT01714414,NCT04296695,NCT02777229,NCT05295394,NCT02770508,NCT03272347,NCT02605954,NCT02469246,NCT02603120,NCT04155554,NCT03870438,NCT01352715,NCT01772940,NCT01489046,NCT03311945,NCT02566707,NCT04429152,NCT04549467,NCT04884139,NCT00772902,NCT00799864,NCT04880395
|
Herpes simplex infectionDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1F00 |
NCT01829802,NCT02150993,NCT04303598
|
Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecifiedDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1C62.Z |
NCT01620944,NCT00455585,NCT00643968,NCT00002386,NCT00004998,NCT02105987,NCT00099359,NCT01622790,NCT01608269,NCT00627055,NCT00336778,NCT00017719,NCT00001067,NCT00143689,NCT00000952,NCT00002391,NCT00001084,NCT00001066,NCT00004852,NCT01618305,NCT00001644,NCT00002368,NCT00640263,NCT00004736,NCT00335270,NCT00002424,NCT01641809,NCT02116660,NCT00002389,NCT00256828,NCT02431975,NCT01599364,NCT00234923,NCT00014014,NCT00337922,NCT00000838,NCT00002423,NCT00053638,NCT00002233,NCT00004981,NCT02596334,NCT00135382,NCT00002371,NCT00000872,NCT00001068,NCT00002416,NCT01905059,NCT00398996,NCT01061151,NCT00244712,NCT01656122,NCT00000834,NCT00428116,NCT00427297,NCT00004999,NCT00002379,NCT00005017,NCT00549198,NCT00112047,NCT00005106,NCT00043953,NCT00050895,NCT00135369,NCT01910402,NCT00031070,NCT02539576,NCT00118898,NCT01127204,NCT00002190,NCT00000831,NCT00440947,NCT00192634,NCT00002367,NCT00002234,NCT00672412,NCT00002241,NCT00028327,NCT02028676,NCT00038220,NCT00002195,NCT00008554,NCT00002227,NCT00005918,NCT00086359,NCT00102960,NCT00002378,NCT00000944,NCT00143728,NCT00146380,NCT00001108,NCT00005000,NCT00001087,NCT00000901,NCT00001085,NCT00405925,NCT00002199,NCT00724711,NCT00001094,NCT00004583,NCT00004578,NCT02499874,NCT00074581,NCT00000903,NCT00099632,NCT00009061,NCT00979706,NCT01307488,NCT00004585,NCT00002442,NCT00002184,NCT02249130,NCT00011895,NCT00985647,NCT00158405,NCT02075593,NCT00000899,NCT01160120,NCT00002451,NCT00740064,NCT00000885,NCT00615810,NCT00158821,NCT00001091,NCT00001095,NCT00000841,NCT00612898,NCT00000902,NCT00000918,NCT00038506,NCT00624195,NCT00084253,NCT00044577,NCT00544128,NCT02181933,NCT00002409,NCT01982396,NCT02263326,NCT00084149,NCT00013520,NCT00332306,NCT00002162,NCT00126880,NCT00943540,NCT00158470,NCT00002436,NCT00002376,NCT00013897,NCT00002320,NCT00120783,NCT02120352,NCT01366547,NCT01174914,NCT00085943,NCT00618176,NCT00312091,NCT00314626,NCT01263015,NCT02403674,NCT00084136,NCT00078247,NCT00002410,NCT00102206,NCT00000865,NCT00127972,NCT01900106,NCT00002183,NCT00094367,NCT00335192,NCT00234091,NCT02159599,NCT00002179,NCT00000870,NCT00002124,NCT00000891,NCT01227824,NCT00000882,NCT00002245,NCT00350272,NCT00046176,NCT00270296,NCT02131025,NCT00005002,NCT00002429,NCT01386970,NCT00344760,NCT00312039,NCT00000940,NCT00338390,NCT00002208,NCT00342355,NCT00885482,NCT01751555,NCT01511237,NCT00273975,NCT02300623,NCT00307151,NCT00424814,NCT00000916,NCT00001083,NCT00164736
|
HIV-infected patients with tuberculosisDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1B10-1B14 |
NCT00078247,NCT00332306
|
Hepatic fibrosis/cirrhosisDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DB93 |
NCT01718587,NCT00275652
|
Mature T-cell lymphomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2A90 |
NCT00041327,NCT01528865
|
Renal cell carcinoma, chromophobe typeDisease Category: X.Extension CodesDisease ICD-11 Code: XH6153 |
CYP1A2,CYP1A1
|
Congenital human immunodeficiency virus infectionDisease Category: 19.Certain conditions originating in the perinatal periodDisease ICD-11 Code: KA62.6 |
NCT00144183,NCT01469520,NCT00958100,NCT02369406,NCT00197613,NCT00433056,NCT02284035,NCT00966160,NCT00100048,NCT03178084,NCT00122538,NCT00116298,NCT02219672,NCT02369965,NCT00001968
|
HyperaldosteronismDisease Category: 05.Endocrine, nutritional or metabolic diseasesDisease ICD-11 Code: 5A72 |
NCT04697121
|
Atopic eczemaDisease Category: 14.Diseases of the skinDisease ICD-11 Code: EA80 |
NCT00533195
|
Human T-cell lymphotropic virus-associated myelopathyDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A45.00 |
NCT00272480
|
Small cell carcinoma of bronchus or lungDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C25.1 |
NCT04696575
|
Alzheimer diseaseDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8A20 |
NCT04552795
|
Amyotrophic lateral sclerosisDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8B60.0 |
NCT05193994
|
DiarrhoeaDisease Category: 21.Symptoms, signs or clinical findings, not elsewhere classifiedDisease ICD-11 Code: ME05.1 |
NCT00650637
|
Hepatocellular carcinoma, NOSDisease Category: X.Extension CodesDisease ICD-11 Code: XH4W48 |
NCT01936233
|
Malignant lymphoma, not elsewhere classifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B33.5 |
NCT00201318
|
Acute viral hepatitisDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1E50 |
NCT00076336
|
Diseases of the urinary system, unspecifiedDisease Category: 16.Diseases of the genitourinary systemDisease ICD-11 Code: GC2Z |
NCT00002397
|
Kaposi sarcomaDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B57 |
NCT00834457
|
Coeliac diseaseDisease Category: 13.Diseases of the digestive systemDisease ICD-11 Code: DA95 |
CYP1A1
|
Serous cystadenoma,borderline malignancy of ovaryDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C73.4 |
CYP1A2
|
Myotonic dystrophyDisease Category: 08.Diseases of the nervous systemDisease ICD-11 Code: 8C71.0 |
CYP1A1
|
Other specified malignant neoplasms ofcolonDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2B90.Y |
CYP1A1
|
Urothelial carcinoma of bladderDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C94.2 |
CYP1A2
|
Cytomegaloviral diseaseDisease Category: 01.Certain infectious or parasitic diseasesDisease ICD-11 Code: 1D82 |
CYP1A1
|
Chronic rhinosinusitisDisease Category: 12.Diseases of the respiratory systemDisease ICD-11 Code: CA0A |
CYP1A1
|
Systemic lupus erythematosusDisease Category: 04.Diseases of the immune systemDisease ICD-11 Code: 4A40.0 |
CYP1A1
|
Malignant neoplasms of corpus uteri, unspecifiedDisease Category: 02.NeoplasmsDisease ICD-11 Code: 2C76.Z |
CYP1A1
|